Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Alabama for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Alabama only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Alabama (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Kun Chen (NPI 1730380056)

Field	Value
Entity Type	Individual
Organization	Kun Chen
Address	4606 Bellewood Dr
City	Huntsville
State	AL
ZIP	35802
Taxonomy	Rheumatology Physician
NPI Enumerated	May 31, 2007

Payer Source	Total Paid
Medicare	$2M
Medicaid	$0

Key Findings

This provider is effectively a Medicare-only biller: lifetime Medicare revenue is listed at $2M while there is no Medicaid billing on file, indicating a single-payer footprint in the available data rather than a mixed Medicare/Medicaid practice profile. Analysts should treat Medicaid as absent for competitive or access analyses since no in-state Medicaid claims are reported.

Revenue concentration is high among a few drug administration codes: the precomputed note says the top three Medicare codes by revenue account for 49.7% of total Medicare revenue, signaling that nearly half of the provider’s Medicare income is driven by a small set of high-revenue services tied to biologic/infusible drugs. This concentration suggests the practice’s economics are strongly linked to infusion and injectable specialty therapies.

The provider’s top revenue code is J0129 (abatacept) at $522.8K, representing 25.6% of Medicare revenue; J1745 (infliximab) and J0717 (certolizumab pegol) follow with $251K and $243.2K respectively. Together these drug administration codes dominate the revenue mix and indicate the practice operates substantial in-office infusion or physician-supervised injectable services consistent with rheumatology specialty care.

Competitive standing on key biologic codes is mixed. J0129 ranks #235 of 1221 providers nationally (81st percentile), a broadly typical volume but above median; J1745 ranks #92 of 1352 providers (93rd percentile), indicating this provider is a high-volume user of infliximab relative to peers; J0717 ranks #315 of 848 (63rd percentile), a more modest national position. Overall, the provider is a meaningful regional participant for certain biologics, particularly infliximab.

E/M visit volumes point to an unusual clinical pattern: 99214 is reported at 1.2K claims with $99.1K revenue and ranks in the 99th percentile as an "extreme outlier, far above typical national volume for this code," while 99213 also sits in very high percentiles. This suggests a heavy reliance on established outpatient visits in addition to infusion services, which may reflect a high patient panel, frequent follow-up cadence, or clinic workflow that documents higher-level E/M activity.

Procedure mix confirms an infusion- and clinic-forward practice model: high-revenue HCPCS chemotherapy/infusion administration codes such as 96413 and 96365, plus multiple biologic J-codes (J0897, J1602, J3111, J9312), appear in the top services list. Lab and procedure codes (86235 ENA panel, 77080 DXA) are present but contribute small shares, reinforcing that the core business is supervised injectable/infusible specialty therapy rather than diagnostic testing.

Tenure data shows this NPI was enumerated around 2007-05-31 (~19 years ago), indicating long-standing Medicare participation. That tenure supports interpretation of billing patterns as established practice behavior rather than a short-term anomaly.

Several ancillary services show consistently above-typical national volumes: lab orders and basic phlebotomy (85025, 36415), vitamin D testing (82306), and ESR (85651) rank in high percentiles, reflecting routine rheumatology monitoring tied to ongoing biologic therapy. These patterns are consistent with chronic disease management workflows associated with immunomodulatory treatments.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

44 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	15,380	$30	$522.8K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	10,040	$30	$251K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	60,800	$1	$243.2K
J0897	Injection, denosumab, 1 mg	12,240	$20	$220.3K
J1602	Injection, golimumab, 1 mg, for intravenous use	19,020	$10	$209.3K
J3111	Injection, romosozumab-aqqg, 1 mg	20,160	$10	$161.3K
J9312	Injection, rituximab, 10 mg	2,410	$60	$154.2K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,210	$80	$99.1K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	890	$60	$53.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	310	$90	$27.3K

Showing 1–10 of 44

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 44 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Alabama Distribution

Kun Chen — 7 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Alabama

Full comparison — all codes billed, vs. state median

44 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	5	30	8,530	$30	$390.9K
J0717	8	10	94,400	$1	$360.6K
J9312	4	10	2,800	$60	$262.7K
J1602	6	20	16,100	$10	$189.5K
J3111	5	10	18,900	$10	$177.3K
J1745	2	30	3,020	$30	$107.2K
J0897	22	200	3,120	$20	$97.7K
86235	4	20	380	$20	$37.9K
96413	43	150	150	$90	$20.2K
99214	95	7,330	120	$80	$16.8K

Showing 1–10 of 44

Related Providers

Other providers that share a Tax Identification Number (TIN) with Kun Chen, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
William Shergy	AL	Rheumatology Physician	$2M	$0
Deepak Sree	AL	Rheumatology Physician	$764.8K	$0
Elijah Mitcham	AL	Rheumatology Physician	$676.9K	$0
Christie Thomas	AL	Rheumatology Physician	$641.5K	$0
Margaret Meehan	AL	Rheumatology Physician	$641.1K	$0
Ayesha Jaleel	AL	Rheumatology Physician	$543.4K	$0
Roxanna Sabghi	AL	Rheumatology Physician	$411.5K	$0

Nearby Providers

Other providers in the same ZIP code as Kun Chen, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Jennifer Kiessling	AL	Cardiovascular Disease Physician	$820.4K	$0
Kelley Smith	AL	Interventional Cardiology Physician	$795.2K	$0
Jitesh Kar	AL	Neurology Physician	$776.8K	$0
Sadasiva Katta	AL	Cardiovascular Disease Physician	$705.5K	$0
United Vascular Of Huntsville, LLC	AL	Ambulatory Surgical Clinic/Center	$584.4K	$0
Warren Strickland	AL	Cardiovascular Disease Physician	$543.1K	$0
James Campbell	AL	Cardiovascular Disease Physician	$484.1K	$0
William Schneider	AL	Cardiovascular Disease Physician	$469.2K	$0
Eric Janssen	AL	Sports Medicine (Orthopaedic Surgery) Physician	$396.2K	$0
James Flatt	AL	Urology Physician	$391.2K	$0

Kun Chen — Billing Profile & Reimbursement Data

Sign up for Kun Chen — Billing Profile & Reimbursement Data policy alerts

Kun Chen — Billing Profile & Reimbursement Data

Sign up for Kun Chen — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References